• Neogenomics Inc NEO.OQ reported quarterly adjusted earnings of 3 cents​​ per share for the quarter ended June 30, identical to the same quarter last year. The mean expectation of fifteen analysts for the quarter was for earnings of 2 cents per share. Wall Street expected results to range from zero cents to 6 cents per share.

• Revenue rose 10.2% to $181.33 million from a year ago; analysts expected $182.69 million.

• Neogenomics Inc's reported EPS for the quarter was a loss of 35 cents​.

• The company reported a quarterly loss of $45.09 million.

• Neogenomics Inc shares had fallen by 11.6% this quarter and lost 60.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 30.7% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

• Wall Street's median 12-month price target for Neogenomics Inc is $12.00, about 46.2% above its last closing price of $6.46

This summary was machine generated from LSEG data July 29 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)